Skip to main content
. 2014 Nov 15;6(2):592–603. doi: 10.18632/oncotarget.2831

Table 2. Examples of Anti-Androgens Approved by the Food and Drug Administration (FDA) agents to treat prostate cancer*.

Drug name Mechanism of action Indication Examples
Leuprolide acetate GnRH** agonists Palliative treatment of advanced prostatic cancer.
Goserelin acetate GnRH agonists Palliative treatment of advanced prostatic cancer.
Triptorelin pamoate GnRH agonists Palliative treatment of advanced prostatic cancer.
Histrelin acetate GnRH agonists Palliative treatment of advanced prostatic cancer.
Degarelix acetate GnRH antagonists Palliative treatment of advanced prostatic cancer.
Bicalutamide Binds to androgen receptor Metastatic prostate cancer
Flutamide Competes for AR the and dihydrotestosterone for the androgen receptor “””
Nilutamide Blocks AR Advanced prostate cancer
Abiraterone acetate CYP17A1 inhibitor Metastatic castration-resistant prostate cancer who have received prior docetaxel.
Enzalutamide Androgen receptor inhibitor Metastatic castration-resistant prostate cancer who have received prior docetaxel.
Radium Ra 223 dichloride Alpha-particle emitting Symptomatic bone metastases and no known visceral metastatic disease.
*

Data from www.fda.gov (Accessed August 11, 2014).

**

AR = androgen receptor; GnRH: gonadotropin releasing hormone.